摘要
肺癌是癌症死亡的主要原因。肺癌的治疗仍是医疗界最具挑战性的任务之一。表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)的发现和发展,对非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗产生了重大影响。但EGFR-TKI对EGFR野生型NSCLC的疗效较差,而有限的EGFR突变率也促使研究者们不断探索EGFR野生型NSCLC的最佳的治疗选择。本文将对EGFR野生型NSCLC的治疗现状进行综述。
Lung cancer is the leading cause of death from cancer in the world. hTe treatment remains one of the most challenging tasks in the medical world. hTe discovery and development of epidermal growth factor receptor-tyrosine ki-nase inhibitor （EGFR-TKI） have had a major impact in the treatment of non small cell lung cancer （NSCLC）. But the effcacy of EGFR-TKI in EGFR wild-type patients is limited, and the limited EGFR mutation incidence also prompts researchers to study what is the best treatment choice for patients with NSCLC who are negative for EGFR mutations. hTis review will discuss the research status in treatment choice for EGFR wild-type NSCLC.
出处
《中国肺癌杂志》
CAS
北大核心
2014年第7期575-580,共6页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
表皮生长因子受体
野生型
化疗
靶向治疗
维持治疗
Lung neoplasms
Epidermal growth factor receptor
Wild type
Chemotherapy
Targeted therapy
Maintenance treatment
